Dexcom Inc Stock Net Income
| DXCM Stock | USD 77.99 0.11 0.14% |
DexCom Inc fundamentals help investors to digest information that contributes to DexCom's financial success or failures. It also enables traders to predict the movement of DexCom Stock. The fundamental analysis module provides a way to measure DexCom's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DexCom stock.
| Last Reported | Projected for Next Year | ||
| Net Income | 541.5 M | 568.6 M | |
| Net Income From Continuing Ops | 541.5 M | 568.6 M | |
| Net Income Applicable To Common Shares | 392.4 M | 412 M | |
| Net Income Per Share | 1.40 | 1.47 | |
| Net Income Per E B T | 0.76 | 0.78 |
DexCom | Net Income |
DexCom Inc Company Net Income Analysis
DexCom's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current DexCom Net Income | 541.5 M |
Most of DexCom's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DexCom Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
DexCom Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for DexCom is extremely important. It helps to project a fair market value of DexCom Stock properly, considering its historical fundamentals such as Net Income. Since DexCom's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of DexCom's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of DexCom's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
DexCom Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, DexCom Inc reported net income of 541.5 M. This is 58.67% higher than that of the Health Care Equipment & Supplies sector and 127.42% higher than that of the Health Care industry. The net income for all United States stocks is 5.16% higher than that of the company.
DexCom Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DexCom's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DexCom could also be used in its relative valuation, which is a method of valuing DexCom by comparing valuation metrics of similar companies.DexCom is currently under evaluation in net income category among its peers.
DexCom ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, DexCom's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to DexCom's managers, analysts, and investors.Environmental | Governance | Social |
DexCom Institutional Holders
Institutional Holdings refers to the ownership stake in DexCom that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of DexCom's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing DexCom's value.| Shares | Nuveen Asset Management, Llc | 2024-06-30 | 6.4 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 6.3 M | Amvescap Plc. | 2024-06-30 | 6.2 M | Norges Bank | 2024-06-30 | 5.4 M | Wellington Management Company Llp | 2024-06-30 | 5.3 M | Bank Of New York Mellon Corp | 2024-06-30 | 4.4 M | Blair William & Co | 2024-06-30 | 4.3 M | American Century Companies Inc | 2024-09-30 | 4 M | Goldman Sachs Group Inc | 2024-06-30 | 3.6 M | Vanguard Group Inc | 2024-09-30 | 47.4 M | Blackrock Inc | 2024-06-30 | 34.5 M |
DexCom Fundamentals
| Return On Equity | 0.32 | ||||
| Return On Asset | 0.0606 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 30.56 B | ||||
| Shares Outstanding | 390.6 M | ||||
| Shares Owned By Insiders | 0.31 % | ||||
| Shares Owned By Institutions | 96.86 % | ||||
| Number Of Shares Shorted | 9.12 M | ||||
| Price To Earning | 245.31 X | ||||
| Price To Book | 15.39 X | ||||
| Price To Sales | 7.72 X | ||||
| Revenue | 3.62 B | ||||
| Gross Profit | 1.88 B | ||||
| EBITDA | 916.7 M | ||||
| Net Income | 541.5 M | ||||
| Cash And Equivalents | 2.37 B | ||||
| Cash Per Share | 6.14 X | ||||
| Total Debt | 2.59 B | ||||
| Debt To Equity | 1.17 % | ||||
| Current Ratio | 3.77 X | ||||
| Book Value Per Share | 5.07 X | ||||
| Cash Flow From Operations | 748.5 M | ||||
| Short Ratio | 1.86 X | ||||
| Earnings Per Share | 1.65 X | ||||
| Price To Earnings To Growth | 1.22 X | ||||
| Target Price | 95.26 | ||||
| Number Of Employees | 9.5 K | ||||
| Beta | 1.17 | ||||
| Market Capitalization | 30.51 B | ||||
| Total Asset | 6.26 B | ||||
| Retained Earnings | 1.02 B | ||||
| Working Capital | 2.87 B | ||||
| Current Asset | 231.3 M | ||||
| Current Liabilities | 66.9 M | ||||
| Net Asset | 6.26 B |
About DexCom Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DexCom Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DexCom using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DexCom Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out DexCom Piotroski F Score and DexCom Altman Z Score analysis. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.157 | Earnings Share 1.65 | Revenue Per Share 10.089 | Quarterly Revenue Growth 0.02 | Return On Assets 0.0606 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.